Access
To read this story in full you will need to login or make a payment (see right).
News
Nature Medicine 11, 359 (2005)
doi:10.1038/nm0405-359a
Tysabri withdrawal calls entire class into question
Emily Singer1
- Boston
Similar drugs may all pose a risk of infections, experts say.The future of a promising treatment for multiple sclerosis (MS) is in question after two patients takinag the drug were diagnosed with a rare neurological disorder.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Therapy Rituximab and PML risk?informed decisions needed!Nature Reviews Rheumatology News and Views (01 Oct 2009)
